Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Annovis Bio (NYSE:ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases, announced that CEO Maria Maccecchini, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference.
The presentation is scheduled for September 10, 2025, from 12:00-12:30 pm EDT at the Lotte New York Palace Hotel. The company, which develops therapies for Alzheimer's and Parkinson's disease, offers one-on-one meeting opportunities with Dr. Maccecchini through the conference portal.
Annovis Bio (NYSE:ANVS), azienda in fase clinica avanzata che sviluppa terapie per le malattie neurodegenerative, ha annunciato che la CEO Maria Maccecchini, Ph.D., interverrà al H.C. Wainwright 27th Annual Global Investment Conference.
La presentazione è prevista per il 10 settembre 2025, dalle 12:00 alle 12:30 EDT presso il Lotte New York Palace Hotel. La società, che lavora su terapie per l'Alzheimer e il Parkinson, offre la possibilità di incontri individuali con la Dr.ssa Maccecchini tramite il portale della conferenza.
Annovis Bio (NYSE:ANVS), una compañía de plataforma farmacéutica en fase clínica avanzada centrada en enfermedades neurodegenerativas, anunció que la directora ejecutiva Maria Maccecchini, Ph.D., presentará en la H.C. Wainwright 27th Annual Global Investment Conference.
La presentación está programada para el 10 de septiembre de 2025, de 12:00 a 12:30 pm EDT en el Lotte New York Palace Hotel. La empresa, que desarrolla terapias para el Alzheimer y el Parkinson, ofrece oportunidades de reuniones uno a uno con la Dra. Maccecchini a través del portal de la conferencia.
Annovis Bio (NYSE:ANVS), 신경퇴행성 질환을 중심으로 하는 후기 임상 단계의 약물 플랫폼 회사인 Annovis Bio는 최고경영자(CEO) Maria Maccecchini 박사가 H.C. Wainwright 제27회 연례 글로벌 투자 컨퍼런스에서 발표할 예정이라고 발표했습니다.
발표 일정은 2025년 9월 10일, 동부 표준시(EDT) 기준 오후 12:00–12:30이며 장소는 롯데 뉴욕 팰리스 호텔입니다. 알츠하이머 및 파킨슨 병 치료제를 개발하는 이 회사는 컨퍼런스 포털을 통해 Maccecchini 박사와의 일대일 미팅 기회도 제공합니다.
Annovis Bio (NYSE:ANVS), une société de plateforme pharmaceutique en phase clinique avancée spécialisée dans les maladies neurodégénératives, a annoncé que sa PDG Maria Maccecchini, Ph.D., prendra la parole lors de la H.C. Wainwright 27th Annual Global Investment Conference.
La présentation est prévue le 10 septembre 2025, de 12h00 à 12h30 EDT au Lotte New York Palace Hotel. La société, qui développe des traitements pour la maladie d'Alzheimer et la maladie de Parkinson, propose des rendez‑vous individuels avec la Dr Maccecchini via le portail de la conférence.
Annovis Bio (NYSE:ANVS), ein in der späten klinischen Phase tätiges Pharmaunternehmen mit Schwerpunkt auf neurodegenerativen Erkrankungen, gab bekannt, dass CEO Maria Maccecchini, Ph.D., auf der H.C. Wainwright 27th Annual Global Investment Conference auftreten wird.
Die Präsentation ist für den 10. September 2025, von 12:00 bis 12:30 Uhr EDT im Lotte New York Palace Hotel angesetzt. Das Unternehmen, das Therapien für Alzheimer und Parkinson entwickelt, bietet über das Konferenzportal Einzelgespräche mit Dr. Maccecchini an.
- None.
- None.
MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its CEO, Maria Maccecchini, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference happening September 8-10, 2025 in Lotte New York Palace Hotel, New York City.
Presentation details
- Date: September 10, 2025
- Time: 12:00-12:30 pm EDT
- Location: Kennedy II, 4th Floor
- Webcast link
To schedule a one-on-one meeting with Dr. Maccecchini, please use the conference portal or contact meetings@hcwco.com.
For more information, please visit conference website.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
FAQ
When and where is Annovis Bio (ANVS) presenting at the H.C. Wainwright Conference?
How can investors schedule meetings with Annovis Bio's CEO at the H.C. Wainwright Conference?
What types of diseases does Annovis Bio (ANVS) focus on?
Who is presenting on behalf of Annovis Bio at the H.C. Wainwright Conference?
